Join Drama Therapist Carlos Rodriguez-Perez at the Expressive Therapies Summit, Thurs, Nov 6, 2025 from 7-9 pm ET

The field of psychedelics is expanding rapidly in the United States. The use of ketamine for the treatment of depression has become a common off-label indication, supported by some insurance companies. Currently, there are several trials exploring the therapeutic potential of psilocybin for the treatment of depression, PTSD and addictions. Models for Psychedelic-Assisted-Psychotherapy (PAP) are being developed for the facilitation of these interventions. Creative Arts Therapists are well positioned to not only support the development of this field, but also to lead the way in which the experience can be facilitated and integrated. Creative Arts Therapists have developed a robust body of knowledge on how to assist clients in processing trauma and life experiences. The embodied nature of the creative arts therapies practices can bring into this field a wealth of knowledge. In this presentation, we aim to review what psychedelics are and which ones are currently being used in the USA. Reviewing some of the current research trials and their target therapeutic impacts, we will seek to explore the skill set and knowledge bases that creative arts therapists can bring into this field. Of importance would also be to understand the opportunities for Creative Arts Therapists to uplift and challenge notions of access and equity as it relates to use of psychedelics as treatment modality.

To register go to: https://www.expressivetherapiessummit.com/fallvirtual

Eligible for 2.0 Clock/Credit Hours: NBCC, ATCB, SWNYS, NY LMHC, NY LCAT, NY LMFT